Novel liquid biopsy tools allowing for diagnosis and prognostic prediction for gastric cancer (GC) patients are urgently ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...

Neoadjuvant ICIs in hepatocellular carcinoma may predict improved relapse-free survival post-resection ... among patients ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member ...

Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2 ... rates and outcomes. The results from DESTINY-Breast06 [NCT04494425] show that Enhertu has the ...

These studies evaluate the efficacy of evorpacept in combination with pembrolizumab and chemotherapy in frontline head and neck squamous cell carcinoma (HNSCC), with a focus on achieving superior ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

The following is a summary of “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage ...